APA (7th ed.) Citation

M, F., AV, A., F, C., SAM, C., MK, D., P, G., . . . JD, G. (2026). Baseline characteristics of patients with transthyretin amyloidosis with cardiomyopathy in the CARDIO-TTRansform trial of eplontersen. European journal of heart failure. https://doi.org/10.1093/ejhf/xuag168

Chicago Style (17th ed.) Citation

M, Fontana, et al. "Baseline Characteristics of Patients with Transthyretin Amyloidosis with Cardiomyopathy in the CARDIO-TTRansform Trial of Eplontersen." European Journal of Heart Failure 2026. https://doi.org/10.1093/ejhf/xuag168.

MLA (9th ed.) Citation

M, Fontana, et al. "Baseline Characteristics of Patients with Transthyretin Amyloidosis with Cardiomyopathy in the CARDIO-TTRansform Trial of Eplontersen." European Journal of Heart Failure, 2026, https://doi.org/10.1093/ejhf/xuag168.